Navigation Links
Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
Date:2/19/2009

ains unchanged from that provided at the time of our third quarter earnings statement. At that time, we provided details of the effect of changes in foreign exchange rates on the earnings guidance. Specifically, our plans for 2009, supporting Non GAAP diluted earnings per ADS for 2009 in the range of $3.00 to $3.40, were based on average actual foreign exchange rates (EUR1:$1.52, GBP1:$1.95) for the ten months to October 2008.

We identified that each 10c movement in the EUR:$ and GBP:$ exchange rates impacts Shire's Non GAAP diluted earnings per ADS by $0.10 and $0.01 respectively. We are unable to provide any forecast on the outcome of foreign exchange movements during 2009, but based on the following exchange rate scenarios the impact on our base guidance would be:

                                  Euro fx     GBP fx     Non GAAP diluted
                                  rate        rate       earnings per ADS
                                                         range
    Base guidance                 $1.52       $1.95      $3.00 to $3.40
    At average October 2008
     exchange rates               $1.35       $1.70      $2.80 to $3.20

    At average January 2009
     exchange rates               $1.33       $1.45      $2.76 to $3.16

Our guidance framework for Non GAAP diluted earnings per ADS is not prepared in accordance with US GAAP. Non GAAP diluted earnings per ADS excludes the effect of certain cash and non-cash items, both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire's business. A list of these items can be found on pages 6-7.

NEW PRODUCT LAUNCHES

Subject to obtaining the relevant regulatory/governmental approvals, product launches planned over the next two years include:

    - MEZAVANT (mesalazine) for use in the treatment of ulcerative
      colitis in certain EU countrie
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related biology technology :

1. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
2. Shire plc: Change to Directors Details
3. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
4. Shires New Product Portfolio Delivers Strong Quarterly Performance
5. Change of Name to Shire plc
6. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
7. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
8. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
9. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
10. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
11. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- The International Society for Medical Publication Professionals ... continuing to accept abstracts for its 6th Annual ... April 19-21, 2010. This marks the first time ... the organization to submit an abstract to this ... AM EST, January 15, 2010. For submission details, ...
(Date:12/15/2009)... N.Y., Dec. 15 On January 20th, ... Society for Medical Publication Professionals (ISMPP) will be ... London, UK. More than 100 attendees are expected ... for publication professionals, editors, publishers, medical writers and ... medical publications and the impact of guidelines and ...
(Date:12/15/2009)... -- , - 45 ... Ability of,Cardiopoietic Cells to Restore Cardiac Function ,, ... Belgian biotechnology company specialising,in cell-based therapies for the ... completed, two months ahead of schedule,enrolment in the ... of C-Cure, a,unique stem cell therapy for heart ...
(Date:12/14/2009)... and THOUSAND OAKS, Calif., Dec. 14 ... Amgen Inc.(Nasdaq: AMGN ) today announced that ... worldwide rights to Array,s small-molecule glucokinase activator program, ... 1 clinical trial in patients with Type 2 ... the agreement, Array will receive an upfront payment ...
Breaking Biology Technology:The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7
... the leading,management consulting firm specializing in the pharmaceutical ... President,in the firm,s Sales Practice, will present a ... The event will be held from,April 2 to ... Spain., Mr. Schmidt,s 90-minute workshop, titled "Positioning ...
... BEIJING and CLAREMONT, Calif., March 26 /Xinhua-PRNewswire-FirstCall/,-- Kiwa ... that revenues for the year ended December 31, ... for 2006., Net sales from continuing operations ... December 31, 2007 and 2006, respectively,representing an increase ...
... Inc.,(Amex: PIP ) a biodefense company ... countermeasures against chemical and,biological terrorism, announced today ... providing an additional value of $5.8 million ... spectrum chemical nerve,agent prophylaxis., In September ...
Other Biology Technology:Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 2Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 2Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 4Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 5Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 6Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 7Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthene's Protexia(R) Program 2Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthene's Protexia(R) Program 3Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthene's Protexia(R) Program 4
(Date:12/15/2009)... Ghent, 15 December 2009 - Scientists at VIB and ... ally for the treatment of septic shock, the major ... the release of nitric oxide (NO) gas in mice ... discovered that the animal,s organs showed much less damage, ... to all expectations, since it is generally assumed that ...
(Date:12/15/2009)... the near future, consumers can look forward to ... as laptops, PDAs and mobile phones. This is ... harvesting technologies which are critical elements for power ... and systems. , Analog IC design is the ... harvesting. To pre-position the nation in advanced analog ...
(Date:12/14/2009)... -- Researchers at Rice University and Baylor College of ... be tracked in real time with MRI as it ... fluorescent dye and kills them with heat. The all-in-one ... growing field called "theranostics" that develops technologies physicians can ... procedure. , The research is available online in the ...
Breaking Biology News(10 mins):Septic shock: Nitric oxide beneficial after all 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Tracking new cancer-killing particles with MRI 2Honoring Those Who Help Make Blood Safe and Available 56839 1Honoring Those Who Help Make Blood Safe and Available 56839 2Honoring Those Who Help Make Blood Safe and Available 56839 3Most Pharmaceutical Companies Receive Poor Grades on HIV AIDS Drug Development Innovation According to AIDS Treatment Activist Coalition Report Card 56837 1Most Pharmaceutical Companies Receive Poor Grades on HIV AIDS Drug Development Innovation According to AIDS Treatment Activist Coalition Report Card 56837 2Most Pharmaceutical Companies Receive Poor Grades on HIV AIDS Drug Development Innovation According to AIDS Treatment Activist Coalition Report Card 56837 3Allied Worlds David Bell to Present as Keynote Speaker at 2009 Entrepreneurial Insurance Symposium 56835 1Allied Worlds David Bell to Present as Keynote Speaker at 2009 Entrepreneurial Insurance Symposium 56835 2Allied Worlds David Bell to Present as Keynote Speaker at 2009 Entrepreneurial Insurance Symposium 56835 3
... WI, MAY 18, 2009 Pharmaceuticals and personal care ... sludge) may reach surface waters or groundwater when ... land. During the high flow conditions created by ... residence time of solutes in soil macropores may ...
... Barron and his group, working with labs in Italy, Germany ... means by which the deadly virus spreads by taking away ... computer simulations, researchers tested more than 100 carbon fullerene, or ... see if they could be used to inhibit a strain ...
... a patient,s healthy tissue as well as eradicating the ... especially invasive and often causing nasty side effects. , ... more precise and accurate treatment for cancerous tumours by ... Real-time image-guided radiotherapy, combining radiation treatment with non-invasive MR ...
Other Biology News:Simulating pharmaceutical and personal care product transport 2International team tracks clues to HIV 2International team tracks clues to HIV 3